A Phase 1 interventional study of TAK-228 in Advanced Nonhematological Neoplasms, sponsored by Calithera Biosciences, Inc. Terminated at 4 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-08.
Sponsored by Calithera Biosciences, Inc · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the safety and tolerability, recommended phase 2 dose (RP2D), and to characterize PK of TAK-228 administered once daily or once weekly to East Asian participants with advanced nonhematological malignancies.
The drug being tested in this study is called TAK-228. TAK-228 is being tested to treat East Asian participants with advanced nonhematological malignancies for whom standard anticancer treatment is not available or is no longer effective. This study will assess the safety, tolerability, PK and will determine the RP2Ds of TAK-228.
The study will enroll approximately 46 participants, including at least 6 Japanese participants at RP2D dose level. Participants will be assigned to one of the following treatment arms:
This multi-center trial will be conducted in South Korea, Taiwan, and Japan. The overall time to participate in this study is up to 12 months, unless in the opinion of the investigator and sponsor the participant would derive benefit from continued therapy beyond 12 months. Participants will be followed for 30 days after last dose of study drug for a follow-up assessment.
Calithera Biosciences, Inc is the lead sponsor of 29 studies on the registry; none are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 10 (59%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
With advanced nonhematologic , with the exception of primary brain tumor, and have failed or are not eligible for standard of care therapy. History of may be allowed if all of the following criteria are met:
Screening clinical laboratory values as specified below:
Note: Prophylactic transfusions of blood products or any prophylactic use of hematopoietic growth factors (such as erythropoietin, thrombopoietin, granulocyte colony stimulating factor [G-CSF], and granulocyte macrophage colony stimulating factor [GM-CSF]) is not permitted during the screening period.
Adequate renal function, defined as meeting any 1 of the following criteria:
Exclusion Criteria:
Significant active cardiovascular or pulmonary disease before the first dose of study drug, including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TAK-228, milled capsule, orally, once daily, on an empty stomach in a 28-day treatment cycle for up to 12 months or until disease progression or unacceptable toxicity or withdrawal of consent with a starting dose of 2 milligram (mg) in Cohort 1. Dose escalation will follow a standard 3+3 schema. If 2 mg, once daily, is safe and tolerable, then the dose will be escalated to 4 mg, once daily, until RP2D is determined.
Drug: TAK-228
TAK-228, milled capsule, orally, once weekly, on an empty stomach in Cycle 1 of a 28-day treatment cycle and following a light meal from Cycle 2 for up to 12 months or until disease progression or unacceptable toxicity or withdrawal of consent with a starting dose of 20 mg in Cohort 1. Dose escalation will follow a standard 3+3 schema. If 20 mg, once weekly, is safe and tolerable, then the dose will be escalated to 30 mg, once weekly, until RP2D is determined.
Drug: TAK-228
TAK-228 Capsules.
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Time frame: Baseline up to 30 days after the last dose of study drug (up to Cycle 12 Day 58) (Cycle length= 28 days)
Number of Participants With Grade 3 or Higher TEAEs
Adverse event (AE) Grades were evaluated as per National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE), version 4.03. Grade 1 scaled as Mild; Grade 2 scaled as Moderate; Grade 3 scaled as severe or medically significant but not immediately life-threatening; Grade 4 scaled as life-threatening consequences; and Grade 5 scaled as death related to AE.
Time frame: Baseline up to 30 days after the last dose of study drug (up to Cycle 12 Day 58) (Cycle length= 28 days)
Number of Participants With Serious TEAEs
Time frame: Baseline up to 30 days after the last dose of study drug (up to Cycle 12 Day 58) (Cycle length= 28 days)
Dose Escalation Phase: Number of Participants With Dose-limiting Toxicities (DLTs) During Cycle 1
Toxicity was evaluated according to NCI CTCAE version 4.03. DLT was defined as any of the following occurred events within the first 28 days of the administration of TAK-228 that were considered by investigator to be possibly related to therapy: Grade \>=3 nonhematologic toxicity except for inadequately treated Grade 3 nausea and/or vomiting and diarrhea, Grade 3 hyperglycemia lasting \<=14 days, Grade 3 rash lasting \<=3 days; Grade 3 thrombocytopenia with hemorrhage or requiring platelet transfusion; Grade 3 anemia requiring blood transfusion; Grade 4 neutropenia lasting \>7 days; Grade \>=3 neutropenia of any duration with fever \>=38.5 degree celsius and/or systemic infection; Any other \>=Grade 4 hematologic toxicity; Inability to administer at least 75 percent (%) of planned doses of TAK-228 within Cycle 1 due to treatment-related toxicity and any clinically significant occurrence that the investigators and sponsor agreed would place participants at an undue safety risk.
Time frame: Baseline up to Day 28 in Cycle 1 (Cycle length= 28 days)
Number of Participants With TEAEs Leading to Study Drug Discontinuation
Time frame: Baseline up to 30 days after the last dose of study drug (up to Cycle 12 Day 58) (Cycle length= 28 days)
Cmax: Maximum Observed Plasma Concentration for TAK-228 on Cycle 1 Day 1
Time frame: Cycle 1 Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose (Cycle length= 28 days)
Cmax: Maximum Observed Plasma Concentration for TAK-228 on Cycle 1 Day 15
Time frame: Cycle 1 Day 15 pre-dose and at multiple time points (up to 24 hours) post-dose (Cycle length= 28 days)
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-228 on Cycle 1 Day 1
Time frame: Cycle 1 Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose (Cycle length= 28 days)
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-228 on Cycle 1 Day 15
Time frame: Cycle 1 Day 15 pre-dose and at multiple time points (up to 24 hours) post-dose (Cycle length= 28 days)
Daily Dosing Arms, AUC24: Area Under the Plasma Concentration-time Curve From 0 to 24 Hours for TAK-228 on Cycle 1 Day 1
Time frame: Cycle 1 Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose (Cycle length= 28 days)
Daily Dosing Arms, AUC24: Area Under the Plasma Concentration-time Curve From 0 to 24 Hours for TAK-228 on Cycle 1 Day 15
Time frame: Cycle 1 Day 15 pre-dose and at multiple time points (up to 24 hours) post-dose (Cycle length= 28 days)
Weekly Dosing Arms, AUC168: Area Under the Concentration-time Curve From 0 to 168 Hours for TAK-228 on Cycle 1 Day 1
Time frame: Cycle 1 Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose (Cycle length= 28 days)
Weekly Dosing Arms, AUC168: Area Under the Concentration-time Curve From 0 to 168 Hours for TAK-228 on Cycle 1 Day 15
Time frame: Cycle 1 Day 15 pre-dose and at multiple time points (up to 168 hours) post-dose (Cycle length= 28 days)
AUClast: Area Under the Plasma Concentration-time Curve From 0 to Time of Last Measurable Concentration for TAK-228 on Cycle 1 Day 1
Time frame: Cycle 1 Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose (Cycle length= 28 days)
AUClast: Area Under the Plasma Concentration-time Curve From 0 to Time of Last Measurable Concentration for TAK-228 on Cycle 1 Day 15
Time frame: Cycle 1 Day 15 pre-dose and at multiple time points (up to 168 hours) post-dose (Cycle length= 28 days)
AUC∞: Area Under the Plasma Concentration-time Curve From 0 to Infinity for TAK-228 on Cycle 1 Day 1
Time frame: Cycle 1 Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose (Cycle length= 28 days)
Clinical Benefit Rate (CBR)
The CBR was defined as the percentage of participants with a best overall response (BOR) of complete response (CR), partial response (PR), or stable disease (SD). BOR was defined as the best response recorded after the first dose of study drug until subsequent therapy. As per Response Evaluation Criteria Solid Tumors (RECIST) version 1.1 guidelines, CR was defined as disappearance of all target lesions and non-target lesions, and normalization of tumor marker level. PR was defined as \>= 30% decrease in the sum of the longest diameter (LD) of target lesions, no progression in non-target lesion, and no new lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression (PD). PD was defined as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
Time frame: Baseline Up to 1 Year 7 Months
Participants took part in the study at 4 investigative sites in Japan, South Korea and Taiwan from 17 January 2018 to 28 August 2019.
| Milestone | Dose Escalation, Daily Dosing Arm: TAK-228 2 mg | Dose Escalation, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Daily Dosing Arm: TAK-228 4 mg | Dose Expansion, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 20 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 30 mg |
|---|---|---|---|---|---|---|
| Started | 3 | 6 | 7 | 0 | 3 | 3 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 3 | 6 | 7 | 0 | 3 | 3 |
| Withdrew: Other | 0 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 2 | 0 | 0 | 2 |
| Withdrew: Adverse event | 1 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Progressive disease | 2 | 4 | 2 | 0 | 3 | 1 |
| Milestone | Dose Escalation, Daily Dosing Arm: TAK-228 2 mg | Dose Escalation, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Daily Dosing Arm: TAK-228 4 mg | Dose Expansion, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 20 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 30 mg |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 6 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 6 | 0 | 0 |
| Withdrew: Progressive disease | 0 | 0 | 0 | 6 | 0 | 0 |
| Participants | Dose Escalation, Daily Dosing Arm: TAK-228 2 mg | Dose Escalation, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Daily Dosing Arm: TAK-228 4 mg | Dose Expansion, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 20 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 30 mg |
|---|---|---|---|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 3 | 6 | 7 | 6 | 3 | 3 |
Adverse event (AE) Grades were evaluated as per National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE), version 4.03. Grade 1 scaled as Mild; Grade 2 scaled as Moderate; Grade 3 scaled as severe or medically significant but not immediately life-threatening; Grade 4 scaled as life-threatening consequences; and Grade 5 scaled as death related to AE.
| Participants | Dose Escalation, Daily Dosing Arm: TAK-228 2 mg | Dose Escalation, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Daily Dosing Arm: TAK-228 4 mg | Dose Expansion, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 20 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 30 mg |
|---|---|---|---|---|---|---|
| Number of Participants With Grade 3 or Higher TEAEs | 1 | 2 | 6 | 5 | 3 | 1 |
| Participants | Dose Escalation, Daily Dosing Arm: TAK-228 2 mg | Dose Escalation, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Daily Dosing Arm: TAK-228 4 mg | Dose Expansion, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 20 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 30 mg |
|---|---|---|---|---|---|---|
| Number of Participants With Serious TEAEs | 0 | 2 | 3 | 1 | 2 | 1 |
Toxicity was evaluated according to NCI CTCAE version 4.03. DLT was defined as any of the following occurred events within the first 28 days of the administration of TAK-228 that were considered by investigator to be possibly related to therapy: Grade \>=3 nonhematologic toxicity except for inadequately treated Grade 3 nausea and/or vomiting and diarrhea, Grade 3 hyperglycemia lasting \<=14 days, Grade 3 rash lasting \<=3 days; Grade 3 thrombocytopenia with hemorrhage or requiring platelet transfusion; Grade 3 anemia requiring blood transfusion; Grade 4 neutropenia lasting \>7 days; Grade \>=3 neutropenia of any duration with fever \>=38.5 degree celsius and/or systemic infection; Any other \>=Grade 4 hematologic toxicity; Inability to administer at least 75 percent (%) of planned doses of TAK-228 within Cycle 1 due to treatment-related toxicity and any clinically significant occurrence that the investigators and sponsor agreed would place participants at an undue safety risk.
| Participants | Dose Escalation, Daily Dosing Arm: TAK-228 2 mg | Dose Escalation, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Daily Dosing Arm: TAK-228 4 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 20 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 30 mg |
|---|---|---|---|---|---|
| Dose Escalation Phase: Number of Participants With Dose-limiting Toxicities (DLTs) During Cycle 1 | 0 | 0 | 3 | 0 | 0 |
| Participants | Dose Escalation, Daily Dosing Arm: TAK-228 2 mg | Dose Escalation, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Daily Dosing Arm: TAK-228 4 mg | Dose Expansion, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 20 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 30 mg |
|---|---|---|---|---|---|---|
| Number of Participants With TEAEs Leading to Study Drug Discontinuation | 1 | 0 | 2 | 0 | 0 | 1 |
| nanogram per milliliter (ng/mL) | Dose Escalation, Daily Dosing Arm: TAK-228 2 mg | Dose Escalation, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Daily Dosing Arm: TAK-228 4 mg | Dose Expansion, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 20 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 30 mg |
|---|---|---|---|---|---|---|
| Cmax: Maximum Observed Plasma Concentration for TAK-228 on Cycle 1 Day 1 | 23.83 ± 9.6 | 41.35 ± 29.6 | 55.25 ± 26.2 | 41.78 ± 23.7 | 252.29 ± 75.2 | 268.61 ± 57.8 |
| ng/mL | Dose Escalation, Daily Dosing Arm: TAK-228 2 mg | Dose Escalation, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Daily Dosing Arm: TAK-228 4 mg | Dose Expansion, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 20 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 30 mg |
|---|---|---|---|---|---|---|
| Cmax: Maximum Observed Plasma Concentration for TAK-228 on Cycle 1 Day 15 | 31.07 ± 48.6 | 46.85 ± 31.6 | 52.68 ± 47.2 | 45.02 ± 44.5 | 182.75 ± 70.5 | 364.58 ± 37.1 |
| hours | Dose Escalation, Daily Dosing Arm: TAK-228 2 mg | Dose Escalation, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Daily Dosing Arm: TAK-228 4 mg | Dose Expansion, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 20 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 30 mg |
|---|---|---|---|---|---|---|
| Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-228 on Cycle 1 Day 1 | 0.870 (0.50 to 2.03) | 0.990 (0.42 to 1.77) | 1.000 (0.50 to 2.00) | 0.500 (0.40 to 1.02) | 0.470 (0.40 to 2.08) | 1.970 (1.00 to 2.02) |
| hours | Dose Escalation, Daily Dosing Arm: TAK-228 2 mg | Dose Escalation, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Daily Dosing Arm: TAK-228 4 mg | Dose Expansion, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 20 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 30 mg |
|---|---|---|---|---|---|---|
| Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-228 on Cycle 1 Day 15 | 1.000 (0.50 to 2.08) | 0.965 (0.52 to 1.98) | 1.500 (0.92 to 3.00) | 1.000 (0.85 to 2.08) | 2.630 (1.97 to 4.10) | 2.000 (0.50 to 2.00) |
| nanogram*hour per milliliter (ng*hr/mL) | Dose Escalation, Daily Dosing Arm: TAK-228 2 mg | Dose Escalation, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Daily Dosing Arm: TAK-228 4 mg | Dose Expansion, Daily Dosing Arm: TAK-228 3 mg |
|---|---|---|---|---|
| Daily Dosing Arms, AUC24: Area Under the Plasma Concentration-time Curve From 0 to 24 Hours for TAK-228 on Cycle 1 Day 1 | 131.0311 ± 43.269 | 192.2467 ± 32.263 | 295.5497 ± 41.724 | 177.9464 ± 38.813 |
| ng*hr/mL | Dose Escalation, Daily Dosing Arm: TAK-228 2 mg | Dose Escalation, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Daily Dosing Arm: TAK-228 4 mg | Dose Expansion, Daily Dosing Arm: TAK-228 3 mg |
|---|---|---|---|---|
| Daily Dosing Arms, AUC24: Area Under the Plasma Concentration-time Curve From 0 to 24 Hours for TAK-228 on Cycle 1 Day 15 | 221.0132 ± 47.912 | 250.4458 ± 29.806 | 341.1219 ± 44.219 | 278.5369 ± 74.527 |
| ng*hr/mL | Dose Escalation, Weekly Dosing Arm: TAK-228 20 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 30 mg |
|---|---|---|
| Weekly Dosing Arms, AUC168: Area Under the Concentration-time Curve From 0 to 168 Hours for TAK-228 on Cycle 1 Day 1 | 1636.7580 ± 49.907 | 2010.5661 ± 53.631 |
| ng*hr/mL | Dose Escalation, Weekly Dosing Arm: TAK-228 20 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 30 mg |
|---|---|---|
| Weekly Dosing Arms, AUC168: Area Under the Concentration-time Curve From 0 to 168 Hours for TAK-228 on Cycle 1 Day 15 | 1860.7705 ± 42.989 | 2958.0487 ± 47.602 |
| ng*hr/mL | Dose Escalation, Daily Dosing Arm: TAK-228 2 mg | Dose Escalation, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Daily Dosing Arm: TAK-228 4 mg | Dose Expansion, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 20 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 30 mg |
|---|---|---|---|---|---|---|
| AUClast: Area Under the Plasma Concentration-time Curve From 0 to Time of Last Measurable Concentration for TAK-228 on Cycle 1 Day 1 | 123.6468 ± 54.137 | 175.6252 ± 45.734 | 306.5602 ± 39.279 | 173.5642 ± 44.339 | 1471.9032 ± 45.692 | 1839.6167 ± 52.905 |
| ng*hr/mL | Dose Escalation, Daily Dosing Arm: TAK-228 2 mg | Dose Escalation, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Daily Dosing Arm: TAK-228 4 mg | Dose Expansion, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 20 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 30 mg |
|---|---|---|---|---|---|---|
| AUClast: Area Under the Plasma Concentration-time Curve From 0 to Time of Last Measurable Concentration for TAK-228 on Cycle 1 Day 15 | 220.1116 ± 47.966 | 240.1012 ± 38.261 | 322.9544 ± 51.178 | 276.9650 ± 74.314 | 1590.2451 ± 38.770 | 2690.2403 ± 45.633 |
| ng*hr/mL | Dose Escalation, Daily Dosing Arm: TAK-228 2 mg | Dose Escalation, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Daily Dosing Arm: TAK-228 4 mg | Dose Expansion, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 20 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 30 mg |
|---|---|---|---|---|---|---|
| AUC∞: Area Under the Plasma Concentration-time Curve From 0 to Infinity for TAK-228 on Cycle 1 Day 1 | 143.6467 ± 51.931 | 204.3414 ± 36.134 | 320.7879 ± 44.795 | 192.1438 ± 41.892 | 1636.7944 ± 49.906 | 2010.7676 ± 53.638 |
The CBR was defined as the percentage of participants with a best overall response (BOR) of complete response (CR), partial response (PR), or stable disease (SD). BOR was defined as the best response recorded after the first dose of study drug until subsequent therapy. As per Response Evaluation Criteria Solid Tumors (RECIST) version 1.1 guidelines, CR was defined as disappearance of all target lesions and non-target lesions, and normalization of tumor marker level. PR was defined as \>= 30% decrease in the sum of the longest diameter (LD) of target lesions, no progression in non-target lesion, and no new lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression (PD). PD was defined as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
| Percentage of participants | Dose Escalation, Daily Dosing Arm: TAK-228 2 mg | Dose Escalation, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Daily Dosing Arm: TAK-228 4 mg | Dose Expansion, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 20 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 30 mg |
|---|---|---|---|---|---|---|
| Clinical Benefit Rate (CBR) | 33 | 50 | 57 | 33 | 67 | 67 |
Collected over TEAEs are AEs that started after the first dose of study drug and no more than 30 days after the last dose of study drug (up to Cycle 12 Day 58). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dose Escalation, Daily Dosing Arm: TAK-228 2 mg | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Dose Escalation, Daily Dosing Arm: TAK-228 3 mg | 0/6 (0%) | 2/6 (33.3%) | 6/6 (100%) |
| Dose Escalation, Daily Dosing Arm: TAK-228 4 mg | 0/7 (0%) | 3/7 (42.9%) | 7/7 (100%) |
| Dose Expansion, Daily Dosing Arm: TAK-228 3 mg | 0/6 (0%) | 1/6 (16.7%) | 6/6 (100%) |
| Dose Escalation, Weekly Dosing Arm: TAK-228 20 mg | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) |
| Dose Escalation, Weekly Dosing Arm: TAK-228 30 mg | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Event | Dose Escalation, Daily Dosing Arm: TAK-228 2 mg | Dose Escalation, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Daily Dosing Arm: TAK-228 4 mg | Dose Expansion, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 20 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 30 mg |
|---|---|---|---|---|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/3 | 0/6 | 0/7 | 0/6 | 1/3 | 0/3 |
| Metastases to central nervous systemNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/3 | 0/6 | 0/7 | 0/6 | 0/3 | 1/3 |
| EnteritisGastrointestinal disorders | 0/3 | 0/6 | 0/7 | 0/6 | 1/3 | 0/3 |
| Cholangitis acuteHepatobiliary disorders | 0/3 | 0/6 | 0/7 | 0/6 | 1/3 | 0/3 |
| Jaundice cholestaticHepatobiliary disorders | 0/3 | 0/6 | 0/7 | 1/6 | 0/3 | 0/3 |
| Cerebrovascular accidentNervous system disorders | 0/3 | 1/6 | 0/7 | 0/6 | 0/3 | 0/3 |
| Renal impairmentRenal and urinary disorders | 0/3 | 1/6 | 0/7 | 0/6 | 0/3 | 0/3 |
| Genital HerpesInfections and infestations | 0/3 | 0/6 | 1/7 | 0/6 | 0/3 | 0/3 |
| SepsisInfections and infestations | 0/3 | 0/6 | 1/7 | 0/6 | 0/3 | 0/3 |
| Acute myocardial infarctionCardiac disorders | 0/3 | 0/6 | 1/7 | 0/6 | 0/3 | 0/3 |
| Event | Dose Escalation, Daily Dosing Arm: TAK-228 2 mg | Dose Escalation, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Daily Dosing Arm: TAK-228 4 mg | Dose Expansion, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 20 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 30 mg |
|---|---|---|---|---|---|---|
| VomitingGastrointestinal disorders | 0/3 | 2/6 | 3/7 | 2/6 | 0/3 | 3/3 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/3 | 2/6 | 4/7 | 3/6 | 3/3 | 1/3 |
| NauseaGastrointestinal disorders | 3/3 | 2/6 | 4/7 | 2/6 | 3/3 | 3/3 |
| Blood alkaline phosphatase increasedInvestigations | 0/3 | 0/6 | 0/7 | 0/6 | 3/3 | 1/3 |
| StomatitisGastrointestinal disorders | 0/3 | 5/6 | 4/7 | 5/6 | 1/3 | 1/3 |
| Weight decreasedInvestigations | 1/3 | 3/6 | 3/7 | 0/6 | 2/3 | 1/3 |
| Aspartate aminotransferase increasedInvestigations | 1/3 | 2/6 | 1/7 | 2/6 | 2/3 | 1/3 |
| Alanine aminotransferase increasedInvestigations | 0/3 | 1/6 | 1/7 | 2/6 | 2/3 | 1/3 |
| Decreased appetiteMetabolism and nutrition disorders | 2/3 | 1/6 | 4/7 | 4/6 | 2/3 | 1/3 |
| Platelet count decreasedInvestigations | 0/3 | 1/6 | 2/7 | 3/6 | 0/3 | 1/3 |
The safety analysis set included participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Dose Escalation, Daily Dosing Arm: TAK-228 2 mg | Dose Escalation, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Daily Dosing Arm: TAK-228 4 mg | Dose Expansion, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 20 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 30 mg | Total |
|---|---|---|---|---|---|---|---|
| Mean | 69.0 ± 5.20 | 55.8 ± 12.59 | 58.7 ± 10.36 | 56.3 ± 11.5 | 57.0 ± 6.93 | 54.0 ± 12.49 | 58 ± 10.59 |
| Sex: Female, Male(Participants) | Dose Escalation, Daily Dosing Arm: TAK-228 2 mg | Dose Escalation, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Daily Dosing Arm: TAK-228 4 mg | Dose Expansion, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 20 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 30 mg | Total |
|---|---|---|---|---|---|---|---|
| Female | 1 | 2 | 3 | 3 | 1 | 2 | 12 |
| Male | 2 | 4 | 4 | 3 | 2 | 1 | 16 |
| Ethnicity (NIH/OMB)(Participants) | Dose Escalation, Daily Dosing Arm: TAK-228 2 mg | Dose Escalation, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Daily Dosing Arm: TAK-228 4 mg | Dose Expansion, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 20 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 30 mg | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 3 | 6 | 7 | 6 | 3 | 3 | 28 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Dose Escalation, Daily Dosing Arm: TAK-228 2 mg | Dose Escalation, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Daily Dosing Arm: TAK-228 4 mg | Dose Expansion, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 20 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 30 mg | Total |
|---|---|---|---|---|---|---|---|
| Japan | 3 | 4 | 3 | 3 | 3 | 1 | 17 |
| Taiwan, Province Of China | 0 | 1 | 1 | 1 | 0 | 0 | 3 |
| Korea, Republic Of | 0 | 1 | 3 | 2 | 0 | 2 | 8 |
| Height(centimeter (cm)) | Dose Escalation, Daily Dosing Arm: TAK-228 2 mg | Dose Escalation, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Daily Dosing Arm: TAK-228 4 mg | Dose Expansion, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 20 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 30 mg | Total |
|---|---|---|---|---|---|---|---|
| Mean | 163.80 ± 10.000 | 167.05 ± 10.135 | 162.64 ± 5.839 | 162.42 ± 10.619 | 170.47 ± 12.003 | 160.73 ± 8.923 | 164.30 ± 8.96 |
| Weight(kilogram (kg)) | Dose Escalation, Daily Dosing Arm: TAK-228 2 mg | Dose Escalation, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Daily Dosing Arm: TAK-228 4 mg | Dose Expansion, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 20 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 30 mg | Total |
|---|---|---|---|---|---|---|---|
| Mean | 63.33 ± 11.201 | 64.87 ± 13.958 | 62.09 ± 11.982 | 61.87 ± 17.490 | 61.43 ± 6.300 | 63.43 ± 10.001 | 62.84 ± 12.08 |
| Smoking Classification(Participants) | Dose Escalation, Daily Dosing Arm: TAK-228 2 mg | Dose Escalation, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Daily Dosing Arm: TAK-228 4 mg | Dose Expansion, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 20 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 30 mg | Total |
|---|---|---|---|---|---|---|---|
| Never Smoked | 3 | 6 | 6 | 6 | 2 | 3 | 26 |
| Moderate Smoker (6-20 Cigarettes/ day) | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Unknown | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Asian Sub-Category(Participants) | Dose Escalation, Daily Dosing Arm: TAK-228 2 mg | Dose Escalation, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Daily Dosing Arm: TAK-228 4 mg | Dose Expansion, Daily Dosing Arm: TAK-228 3 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 20 mg | Dose Escalation, Weekly Dosing Arm: TAK-228 30 mg | Total |
|---|---|---|---|---|---|---|---|
| Japanese | 3 | 4 | 3 | 3 | 3 | 1 | 17 |
| Korean | 0 | 1 | 3 | 2 | 0 | 2 | 8 |
| Chinese | 0 | 1 | 1 | 1 | 0 | 0 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jan 2018 to primary completion in Aug 2019, 19 months.
Results were first posted in Sep 2020, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sapanisertib